Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

Socinski, Mark A.; Jotte, Robert M.; Cappuzzo, Federico; Orlandi, F; Stroyakovskiy, Daniil; Nogami, Naoyuki; Rodríguez-Abreu, Delvys; Moro‐Sibilot, D.; Thomas, Christian A.; Barlési, Fabrice; Finley, Gene Grant; Kelsch, Claudia; Lee, Anthony; Coleman, Shelley; Shen, Yijing; Kowanetz, Marcin; López-Chávez, Ariel; Sandler, Alan N.; Reck, Martin

doi:10.1200/jco.2018.36.15_suppl.9002

Cited by 81 publications

(83 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bevacizumab and new immunotherapies are currently licensed for use in combination with platinum doublets or are being tested in Phase 3 clinical trials [37][38][39][40][41], yet these combinations were not included in our current review. To our knowledge, there are no RCTs conducted among patients with advanced NSCLC that directly compare carboplatin against cisplatin in combination with either bevacizumab or an immunotherapy [42].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis

Griesinger

Korol²,

Kayaniyil³

et al. 2019

Lung Cancer

102

View full text Add to dashboard Cite

Platinum-based chemotherapy is the mainstay of first-line (1L) therapy for advanced non-small cell cancer (NSCLC). The objective of this study was to evaluate the relative efficacy, safety, and health-related quality of life (HRQoL) of carboplatin-versus cisplatin-based chemotherapy in 1L NSCLC. Materials and Methods: A meta-analysis by the Cochrane group (2013) was updated. Systematic searches of CENTRAL, Medline, Embase, Latin American and Caribbean Health Sciences database, clinicaltrials.gov and conference proceedings were conducted to include randomized controlled trials (RCTs) published between 2013-January 2018 which compared carboplatin and cisplatin combined with: gemcitabine, vinorelbine, docetaxel, paclitaxel, irinotecan, or pemetrexed. Endpoints included overall survival (OS), one-year OS, objective response rate (ORR), grade 3/4 drug-related toxicities, and HRQoL. Results: Twelve RCTs (2,048 patients) were identified from 4,139 records for inclusion in the meta-analysis. There were no significant differences in OS (hazards ratio [HR]: 1.08, 95% confidence interval [CI]: 0.96, 1.21) and one-year OS (relative risk [RR]: 0.97, CI: 0.89, 1.07) between carboplatin-and cisplatin-based chemotherapy. A small effect on ORR favouring cisplatin was detected (RR = 0.88; CI: 0.78, 0.99). Differences in drug-related toxicities were observed between carboplatin-and cisplatin-based chemotherapy for thrombocytopenia, anaemia, neurotoxicity, and the risk of nausea/vomiting. Three RCTs comparing HRQoL between carboplatin-and cisplatin-based chemotherapy found no significant differences. Conclusions: This updated evidence base corroborates findings of previous meta-analyses showing no difference in OS between carboplatin-and cisplatin-based chemotherapy, despite a slight benefit in ORR for cisplatin. Toxicity profiles should be considered alongside patients' comorbidities in the choice of therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis

Griesinger

Korol²,

Kayaniyil³

et al. 2019

Lung Cancer

102

View full text Add to dashboard Cite

show abstract

“…VEGF is known to inhibit T-cells and DCs, and to stimulate immunosuppressive Treg. Proof was noted by the phase III IMpower150 study showing that first-line treatment with the combination of atezolizumab and bevacizumab plus carboplatin and paclitaxel prolonged OS in patients with advanced nonsquamous non-small cell lung cancer compared with bevacizumab plus carboplatin and paclitaxel 49. Two large trials evaluating the combination of bevacizumab and atezolizumab in recurrent (ATALANTE) and front-line ovarian cancer (IMagyn050, Table 1) are currently enrolling patients.…”

Section: Immunological Checkpointsmentioning

confidence: 99%

Immunotherapy in ovarian cancer: fake news or the real deal?

Marth¹,

Wieser

Tsibulak

et al. 2019

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Cancer immunotherapy has emerged as one of the most promising approaches in oncology, and comprises the activation of the immune system to induce tumor immune surveillance or to reverse the tumor immune escape. Different therapeutic strategies for ovarian carcinoma have evolved over the years. Already 30 years ago, the first clinical studies focused on modulating the tumor cytokine network with special attention to interferon-mediated immune responses. With the exploration of specific tumor antigens such as NY-ESO-1, which is expressed in ovarian carcinoma and other malignancies, the development of therapeutic cancer vaccines has been pursued initiating the era of personalized anti-cancer medicine. Almost at the same time, the adoptive transfer of genetically modified autologous tumor-reactive T-cells occurred, but response rates in ovarian carcinoma were disappointing. Today, probably the most promising therapeutic approach in this context is the blockade of immune checkpoints, such as programed cell death protein 1 (PD-1) and one of its ligands (PD-L1) or cytotoxic T-cell lymphocyte-associated antigen 4 (CTLA-4), which has demonstrated impressive response rates in malignant melanoma and non-small cell lung cancer. Despite increasing availability of treatment approaches that target tumor immune surveillance in ovarian carcinoma, selecting patient groups that particularly benefit from these treatment modalities is clinically challenging as predictive biomarkers are lacking. Here, we summarize different immunotherapy approaches in ovarian cancer and discuss why immunotherapy in ovarian cancer is still in its infancy.

show abstract

“…L'association atézolizumab-bévacizumab-chimiothérapie est indiquée depuis février 2019 [28] en première ligne pour le traitement pour les patients porteurs d'un CPNPC non épidermoïde, et pour les patients porteurs d'une addiction oncogénique, après échec des thérapies ciblées, selon les données de l'essai IMpower150 [29]. Cette étude a testé, comme biomarqueur prédictif de la réponse à l'immunothérapie, non pas le taux d'expression tumorale de PD-L1 seul, mais un critère composite : la signature génique de l'activation lymphocytaire (T effecteur, Teff) composée du taux d'expression d'ARN messager de trois gènes codants : PD-L1, CXCL9 (une chimiokine induisant la synthèse d'interféron gamma [IFN-g]) et l'IFN-g, une cytokine immunostimulante [30,31]. Cette signature permettrait d'évaluer l'expression de PD-L1 et le type d'immunité présente dans le microenvironnement tumoral avant le traitement.…”

Section: Autres Types De Cancers Thoraciquesunclassified

L’immunothérapie, une révolution en oncologie

Dubois¹,

Ardin²,

André³

et al. 2019

Med Sci (Paris)

View full text Add to dashboard Cite

L’immunothérapie anti-tumorale représente un changement de paradigme majeur où le traitement ne cible plus directement les cellules tumorales mais le patient lui-même, afin de restaurer une immunité anti-tumorale efficace. Parmi les différentes immunothérapies, les inhibiteurs de points de contrôle immunitaire occupent une place centrale dans les options thérapeutiques disponibles de deux cancers au pronostic particulièrement péjoratif: le mélanome malin et le cancer pulmonaire non à petites cellules métastatique. De nombreux essais sont en cours, évaluant la pertinence de ces molécules à des stades plus précoces de la maladie (stratégies adjuvantes ou d’induction) et leur place dans des stratégies combinatoires (associés à de la chimiothérapie, des thérapies ciblées, d’autres types d’immunothérapies, etc.).

show abstract

Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC.

Cited by 81 publications

References 0 publications

Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis

Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis

Immunotherapy in ovarian cancer: fake news or the real deal?

L’immunothérapie, une révolution en oncologie

Contact Info

Product

Resources

About